Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Medexus Pharmaceuticals (MDP.T) building serious value
*originally published January 26, 2023
Medexus Pharmaceuticals (MDP.T) is a Canadian specialty pharma company on a mission to help humanity by bringing previously approved orphan drugs in other jurisdictions to the Canadian and American market.
Its robust portfolio of leading-edge therapeutics continues to grow market share, helping patients across North America improve quality of life. Trading at a fraction of its revenue, the company presents a unique opportunity for investors.
Jody Vance speaks with Ken d’Entremont, CEO and director of Medexus, to get a closer look at the company, its leadership, and what lays ahead for both investors and the medical community.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Medexus (MDP.T) CEO explains sudden drop
Medexus Pharmaceuticals’ (MDP.T) financials are coming!
Medexus Pharma (MDP.T) is an arbitrage in the making
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E111
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023